Description
Key facts
Cell type:HEK-293T,
Species or organism:Human,
Tissue:Kidney,
Form:LiquidSee storage information,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, Homozygous: 13 bp insertion in exon 3
Product details:
We will provide viable cells that proliferate on revival.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our
limited use license
patent pages
Properties and Storage Information:
Gene name-GNAI1, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Zygosity-Homozygous, Shipped at conditions-Dry Ice, Appropriate short-term storage conditions--196°C, Appropriate long-term storage conditions--196°C
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
The protein GNAI1 also known as G protein subunit alpha i1 is part of the G-protein family that plays an important role in signal transduction. GNAI1 has a molecular mass of approximately 40 kDa. It is mainly expressed in neuronal tissues where it interacts with receptors to regulate intracellular signaling pathways. This protein operates by inhibiting adenylate cyclase activity which reduces the production of cyclic AMP (cAMP) in response to extracellular signals.
Biological function summary
GNAI1 acts by interfering with signal transmission across membranes. It is part of the heterotrimeric G-protein complex which is essential for many signaling processes. This complex responds to activation by G-protein-coupled receptors (GPCRs) and modulates various downstream effectors essentially affecting numerous physiological processes like neurotransmission and hormone signaling.
Pathways
GNAI1 plays a significant role in the cyclic AMP (cAMP) signaling pathway and the neuroactive ligand-receptor interaction pathway. In the cAMP pathway GNAI1 associates with receptors like dopamine and serotonin receptors helping to regulate neuronal response and neurotransmitter release. This activity involves interactions with related proteins such as GNB1 and GNG2 which form the beta and gamma subunits of the heterotrimeric G-protein complex.
GNAI1 relates to neuropathic conditions such as epilepsy and depression. Alterations in GNAI1 function can disrupt normal signaling contributing to these disorders. The protein interacts with other proteins in the signaling cascade such as RGS proteins which can affect its function in disease states. Researchers continue to explore how modifications or mutations in GNAI1 might offer potential therapeutic targets for these and similar disorders.
